Navigation Links
Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
Date:3/11/2008

r licensing arrangements; our ability to attract and retain key personnel; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at http://www.sedar.com.

Assumptions underlying our expectations regarding forward-looking statements or information contained in this press release include, among others, that we will raise enough capital, on reasonable terms and in a timely manner; that we will retain our key personnel; that we will obtain the necessary regulatory approvals related to HspE7 and our adjuvant in a timely manner; that enough HspE7 will be available to conduct our planned trials; that we will be able to procure the necessary amount of adjuvant to conduct our planned trials; that we will obtain timely approval from additional IRBs; that the results from additional preclinical and clinical work, if any, will be consistent with the results we have already obtained; that a sufficient number of patients will be available to conduct our planned trials; and that sufficient data will be generated to support our IND.

In the event that any of these assumptions prove to be incorrect, or in the event that we are impacted by any of the risks identified above, we may not be able to continue in our business as planned.

For a complete discussion of the assumptions, risks and uncertainties related to our business, you are encouraged to review our filings with Canadian securities regulatory authorities, including our 2006 Annual Information Form filed on SEDAR at http://www.sedar.com. Historical filings relating to the Company prior to the completion of the Company's March 23, 2006 corporate reorganization, including Old Stressgen's 2005 Annual Information Form dated March 16, 2006 may be reviewed on SEDAR at http://www.sedar.com under the SEDAR profile GVIC
'/>"/>

SOURCE Nventa Biopharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Nventa Evaluation Complete for First Three Cohorts in HspE7 Phase 1 Cervical Dysplasia Trial
2. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
3. Spectranetics Enrolls First Patient in PATENT Trial for the Treatment of Instent Restenosis
4. Ception Therapeutics Initiates Phase II/III Clinical Trial for Its Lead Product Reslizumab in Eosinophilic Esophagitis (EE) in Children
5. Pharmacopeia Initiates Second Phase 2 Hypertension Study with PS433540 (DARA)
6. Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
7. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
8. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
9. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
10. Northwestern Memorial Transplant Program Initiates New Study
11. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... report is available in its catalogue: ... India Drug Forecast and Market Analysis to ... PharmaPoint: Atopic Dermatitis - India Drug ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... Jan. 14, 2014 HeartWare International, Inc . ... less invasive, miniaturized circulatory support technologies that are revolutionizing ... it expects revenues for the fourth quarter of 2013 ... revenues to approximately $208 million. "Our full-year ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
... WellPoint, Inc. (NYSE: WLP ) is the first ... guidelines that it will use when evaluating drugs for purposes of ... plans. , , , ... guidelines in the public domain, we are providing some guidance to pharmaceutical ...
... PFE ) invites investors and the general public to view and listen to a ... at the Citi 2010 Global Healthcare Conference on Wednesday, May 26, 2010 , at ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO ... To view and listen to the webcast, ...
Cached Medicine Technology:WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals 2WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals 3WellPoint Is First Health Benefits Company to Release CER Guidelines for Use in Evaluating Pharmaceuticals 4Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference 2
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
(Date:4/17/2014)... flow and alleviates muscle soreness after exercise, according ... of Illinois at Chicago. , The study, reported ... Archives of Physical Medicine and Rehabilitation , also ... who had not exercised, suggesting that massage has ... physical activity. , Improved circulation and relief of ...
(Date:4/17/2014)... TORONTO, April 17, 2014While 94 per cent of Canadians ... that screen newborns for a specific number of genetic ... willing to participate in screening that would sequence their ... prick test" in their first day or two of ... taken from their heels and tested for about five ...
(Date:4/17/2014)... lost its status as the leading weapon against the ... life, with new research indicating it simply needs to ... use of the cheap anti-malarial drug chloroquine in treating ... of more than half a million people each year ... has developed resistance to chloroquine, but research carried out ...
(Date:4/16/2014)... , PHOENIX, Ariz. April 15, 2014 The ... Arizona philanthropists at their annual Founders Dinner for their ... cancer. The event took place March 28 in Scottsdale. ... & Catherine Ivy Foundation, received TGen,s John S. McCain ...
Breaking Medicine News(10 mins):Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2Health News:Massage therapy improves circulation, eases muscle soreness 2Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:Scientists find new way to fight malaria drug resistance 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... 27 Accuray,Incorporated (Nasdaq: ARAY ), a global ... senior vice president and chief financial officer,Robert E. McNamara, ... Company Ninth,Annual Investor Conference at the Palms Casino & ... 8:00 a.m. PDT (11:00 a.m. EDT)., A live ...
... discussed by international experts, WASHINGTON, March 27 ... the first time, bring together leading heart,disease and stroke ... income, education and geography can predict how healthy we ... held March 28 on the campus of George Washington,University, ...
... MOORESTOWN, N.J., March 27 In response ... problem with medication use in the United,States, ... Rasa,Strategies(TM), LLC (TR-Strategies(TM)), a pharmaceutical care consulting,firm ... practice, to help,organizations develop strategies to implement ...
... 20 Global Pharmaceutical Company Licenses Public-Source Database to, Quantify ... ... Development, MOUNTAIN VIEW, Calif., March 27 ... and regulatory services for optimizing clinical drug,development, today announced that it ...
... Congressman for Formally Opposing Deep,Cuts to Medicare,s Home ... Pacific Pulmonary,Services - Ukiah Center, a provider of ... more than 200 patients in Ukiah and the,surrounding ... with patients, physicians and technicians to discuss the ...
... Election 2008 Resources for Voters on Health Care ... American Academy of,Actuaries said the most recent Medicare ... program,s long-term financing issues.,According to the program,s trustees, ... payroll taxes, and Medicare must,rely also on interest ...
Cached Medicine News:Health News:Accuray's CFO to Present at B. Riley & Company Ninth Annual Investor Conference 2Health News:Groundbreaking Town Hall Meeting to Explore Why Race, Income and Geography Can Predict Health 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 2Health News:Tabula Rasa Strategies(TM), LLC, Announces Their Company Launch - A 'Clean Slate' Approach to the Practice of Pharmaceutical Care 3Health News:Pharsight Signs New Diabetes Meta-Database Customer 2Health News:Pharsight Signs New Diabetes Meta-Database Customer 3Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 2Health News:Ukiah Home Oxygen Therapy Patients and Physicians Meet with Congressman Mike Thompson to Share Benefits of Quality Home Oxygen Care 3Health News:Medicare Trustees' Report Highlights Need for Reform 2
... The Eppendorf Reference Series 2000 Pipette is ... stroke, a compact and robust design, and ... is used to operate the measuring stroke ... tip. Product features:Eppendorf "pipette/tip" system ensures utmost ...
Pipetman F is a fixed-volume, air-displacement pipette. Thirteen robust models cover a large volume range from 2 L to 1000 L, with Gilsons legendary accuracy and precision....
... ergonomics, and value!, Comfortable feel ... non-slip, contoured handle , Finer control ... spring action , Completely autoclavable for ... need for recalibration , Easy-to-read precision ...
Inquire...
Medicine Products: